株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血糖モニタリングシステムの世界市場予測

GLOBAL GLUCOSE MONITORING SYSTEM MARKET FORECAST 2018-2026

発行 Inkwood Research 商品コード 492797
出版日 ページ情報 英文 220 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.52円で換算しております。
Back to Top
血糖モニタリングシステムの世界市場予測 GLOBAL GLUCOSE MONITORING SYSTEM MARKET FORECAST 2018-2026
出版日: 2018年02月19日 ページ情報: 英文 220 Pages
概要

当レポートでは、血糖モニタリングシステムの世界市場について調査し、市場構造、市場成長の促進・阻害要因の分析、持続血糖測定システム(CGMS)および血糖自己測定(SMBG)のコンポーネント・用途別の市場動向、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • 市場促進要因とその影響
  • 市場阻害要因とその影響

第5章 持続血糖測定システム(CGMS)市場:コンポーネント別

  • センサー
  • 送受信機
  • インスリンポンプ

第6章 持続血糖測定システム(CGMS)市場:用途別

  • 診療所
  • 病院
  • 在宅医療

第7章 血糖自己測定(SMBG)市場:コンポーネント別

  • 試験紙
  • 血糖値計
  • その他

第8章 血糖自己測定(SMBG)市場:用途別

  • 在宅医療
  • 診療所
  • 病院

第9章 市場分析

  • ファイブフォース分析
  • 市場動向
  • 主要地域
  • 合併・買収
  • 主要動向

第10章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第11章 競合環境

目次
Product Code: 2229

KEY FINDINGS

The Global Continuous Glucose Monitoring System (CGMS) market stood at $1120 million in 2017. Over the forecast years of 2018-2026, the market is expected to rise at a 32.94% CAGR, generating a net total of $14519.3 million.

Similarly, the Self-monitoring of Blood Glucose (SMBG) market stood at $13192.2 million in 2017. Over the forecast years of 2018-2026, the market is expected to rise at a 7.57% CAGR, generating a net total of $24995.5 million.

MARKET INSIGHTS

The global CGMS market is segmented on the basis of its component types and end users. The component types segment of the market includes sensors, transmitters and receivers, and insulin pump. The end users segment of the market includes home settings, diagnostics and clinics, and hospitals.

The global SMBG market is also segmented on the basis of its component types and end users. The component types segment of the market includes test strips, glucose meter, and lancets. The end users segment of the market includes home settings, clinics, and hospitals.

REGIONAL INSIGHTS

The regional segmentation of the markets is done into North America, Europe, Asia Pacific, Latin America, and rest of the world. The North American market is expected to capture the highest revenue share by 2026, for both CGMS and SMBG markets, driven by high awareness related to diabetes. Latin America and Asia-Pacific are predicted to grow more over the forecast period, owing to the increasing diabetic population in these regions.

COMPETITIVE INSIGHTS

Medtronic, Dexcom, Abbott, Johnson and Johnson, Insulet Corp, Tandem Diabetes Care, Echo Theraperutics Inc., Roche Diagnostics, Nemaura Medical Inc., Senseonics Inc., Glysens Inc., Terumo, Wockhardt, I-Sens Inc., Morpen Laboratories Ltd., Apex Biotechnology Corp., Arkray Inc., B Braun Melsungen AG, and Ascensia are some of the noted market players in the global glucose monitoring systems market.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE STUDY MARKET
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
  • 2.2. BOTTOM-UP APPROACH
  • 2.3. TOP DOWN APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. CGMS MARKET IS ANTICIPATED TO BE THE DEVELOPED MARKET
    • 3.2.2. SELF-MONITORING OF BLOOD GLUCOSE HAS HUGE MARKET OPPORTUNITY
    • 3.2.3. COLLABORATION OF SIGNIFICANT COMPANIES TO DEVELOP INTEGRATED CGMS-ENABLED INSULIN PUMPS

4. MARKET OVERVIEW

  • 4.1. DRIVERS AND IMPACT
    • 4.1.1. RISE IN THE INCIDENCE OF DIABETES
    • 4.1.2. INCREASE IN HEALTHCARE EXPENDITURE
    • 4.1.3. INCREASING FOCUS ON RESEARCH AND DEVELOPMENT
    • 4.1.4. TECHNOLOGY INTEGRATION
    • 4.1.5. INCREASING CGMS AND SMBG AFFORDABILITY
    • 4.1.6. TECHNOLOGICAL ADVANCES IN GMS DEVICES
    • 4.1.7. AWARENESS AMONG THE GENERAL POPULATION
  • 4.2. RESTRAIN AND IMPACT
    • 4.2.1. HINDERANCE FROM GOVERNMENT REGULATIONS

4.2.2 INADEQUATE REIMBURSEMENT OPTIONS FOR CONTINUOUS GLUCOSE MONITORING DEVICES

    • 4.2.3. LACK OF AWARENESS OF THE DIAGNOSTIC OPPORTUNITIES
  • 4.3. CHALLENGES
    • 4.3.1. INTENSE COMPETITION AMONG VENDORS
    • 4.3.2. INACCURACY IN READING OF GMS DEVICES
    • 4.3.3. INCREASINGLY STRINGENT GOVERNMENT REGULATIONS

5. CGMS MARKET SEGMENTATION

  • 5.1. MARKET BY COMPONENT TYPE 2018-2026
    • 5.1.1. SENSORS
    • 5.1.2. TRANSMITTERS AND RECEIVERS
    • 5.1.3. INSULIN PUMP
  • 5.2. MARKET BY END USERS 2018-2026
    • 5.2.1. HOME SETTINGS
    • 5.2.2. DIAGNOSTICS AND CLINICS
    • 5.2.3. HOSPITALS

6. SMBG MARKET

7. SMBG MARKET SEGMENTATION

  • 7.1. MARKET BY COMPONENT TYPE 2018-2026
    • 7.1.1. TEST STRIPS
    • 7.1.2. GLUCOSE METER
    • 7.1.3. LANCETS
  • 7.2. MARKET BY END USERS 2018-2026
    • 7.2.1. HOME SETTINGS
    • 7.2.2. CLINICS
    • 7.2.3. HOSPITALS

8. KEY ANALYTICAL

  • 8.1. 5 FORCES ANALYSIS
    • 8.1.1. THREAT OF NEW ENTRANT
    • 8.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIER
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. MERGER AND ACQUISITIONS
  • 8.3. KEY BUYING CRITERIA
  • 8.4. KEY TRENDS
    • 8.4.1. DEVELOPMENT OF HIGH-QUALITY WEARABLE DEVICES
    • 8.4.2. MOBILE HEALTHCARE MAKING THE DEVICES MORE USER-FRIENDLY
    • 8.4.3. INCREASING EFFORTS TOWARDS SPREAD OF AWARENESS
    • 8.4.4. INCREASE IN NON-INVASIVE DEVICES
    • 8.4.5. ENERGY HARVESTING TECHNOLOGY FOR UNINTERRUPTED USAGE
  • 8.5. REGULATION OF BLOOD SUGAR
  • 8.6. INCIDENCE AND PREVALENCE OF DIABETES FOR VARIOUS COUNTRIES

9. REGIONAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. THE US
      • 9.1.1.1. THE UNITED STATES HEALTH AND HEALTHCARE
      • 9.1.1.2. THE UNITED STATES PHARMACEUTICAL MARKET
    • 9.1.2. CANADA
      • 9.1.2.1. CANADA HEALTH AND HEALTHCARE
      • 9.1.2.2. CANADA PHARMACEUTICAL MARKET
      • 9.1.2.3. CANADA DIABETES MARKET
  • 9.2. EUROPE
    • 9.2.1. GERMANY
      • 9.2.1.1. GERMANY HEALTH AND HEALTHCARE
      • 9.2.1.2. GERMANY PHARMACEUTICAL MARKET
    • 9.2.2. THE UK
      • 9.2.2.1. THE UNITED KINGDOM HEALTH AND HEALTHCARE
      • 9.2.2.2. THE UNITED KINGDOM HEALTHCARE PROVISION
      • 9.2.2.3. THE UNITED KINGDOM PRIVATE SECTOR INVOLVEMENT
      • 9.2.2.4. THE UNITED KINGDOM PHARMACEUTICALS
    • 9.2.3. FRANCE
      • 9.2.3.1. FRANCE HEALTH AND HEALTHCARE
      • 9.2.3.2. FRANCE HEALTHCARE PROVISION
      • 9.2.3.3. MARKET TRENDS
    • 9.2.4. REST OF EUROPE (ROE)
      • 9.2.4.1. ITALY HEALTH AND HEALTHCARE
      • 9.2.4.2. ITALY HEALTHCARE SYSTEM
      • 9.2.4.3. ITALY PHARMACEUTICAL MARKET
      • 9.2.4.4. SPAIN HEALTH AND HEALTHCARE
      • 9.2.4.5. SPAIN HEALTHCARE PROVISION
      • 9.2.4.6. SPAIN PHARMACEUTICAL SERVICES
  • 9.3. ASIA-PACIFIC (APAC)
    • 9.3.1. CHINA
      • 9.3.1.1. CHINA HEALTH AND HEALTHCARE
      • 9.3.1.2. CHINA PHARMACEUTICAL MARKET
      • 9.3.1.3. CHINA DIABETES MARKET
      • 9.3.1.4. MARKET TRENDS
    • 9.3.2. INDIA
      • 9.3.2.1. INDIA HEALTH AND HEALTHCARE
      • 9.3.2.2. INDIA REGULATORY CHANGES
      • 9.3.2.3. INDIA PHARMACEUTICAL MARKET
      • 9.3.2.4. INDIA DIABETES MARKET
      • 9.3.2.5. MARKET TRENDS
    • 9.3.3. AUSTRALIA
      • 9.3.3.1. MARKET TRENDS
    • 9.3.4. JAPAN
      • 9.3.4.1. JAPAN HEALTH AND HEALTHCARE
      • 9.3.4.2. JAPAN PHARMACEUTICAL MARKET
      • 9.3.4.3. JAPAN DIABETES MARKET
      • 9.3.4.4. MARKET TRENDS
    • 9.3.5. SOUTH KOREA
      • 9.3.5.1. MARKET TRENDS
    • 9.3.6. INDONESIA
      • 9.3.6.1. MARKET TRENDS
    • 9.3.7. MALAYSIA
      • 9.3.7.1. MARKET TRENDS
    • 9.3.8. PHILIPPINES
      • 9.3.8.1. MARKET TRENDS
    • 9.3.9. THAILAND
      • 9.3.9.1. MARKET TRENDS
    • 9.3.10. VIET NAM
      • 9.3.10.1. MARKET TRENDS
    • 9.3.11. REST OF ASIA-PACIFIC (ROAP)
  • 9.4. LATIN AMERICA
    • 9.4.1. BRAZIL HEALTH AND HEALTHCARE
    • 9.4.2. BRAZIL PHARMACEUTICAL MARKET
    • 9.4.3. MEXICO HEALTH AND HEALTHCARE
    • 9.4.4. MEXICO PHARMACEUTICAL MARKET
  • 9.5. MIDDLE EAST AND AFRICA (MEA)

10. COMPETITIVE LANDSCAPE

  • 10.1. MEDTRONIC
    • 10.1.1. OVERVIEW
    • 10.1.2. PRODUCT PORTFOLIO
    • 10.1.3. STRATEGIC INITIATIVES
    • 10.1.4. SCOT ANALYSIS
  • 10.2. DEXCOM
    • 10.2.1. OVERVIEW
    • 10.2.2. PRODUCT PORTFOLIO
    • 10.2.3. STRATEGIC INITIATIVES
    • 10.2.4. SCOT ANALYSIS
  • 10.3. ABBOTT
    • 10.3.1. OVERVIEW
    • 10.3.2. PRODUCT PORTFOLIO
    • 10.3.3. STRATEGIC INITIATIVES
    • 10.3.4. SCOT ANALYSIS
  • 10.4. JOHNSON AND JOHNSON
    • 10.4.1. OVERVIEW
    • 10.4.2. PRODUCT PORTFOLIO
    • 10.4.3. STRATEGIC INITIATIVES
    • 10.4.4. SCOT ANALYSIS
  • 10.5. INSULET CORP
    • 10.5.1. OVERVIEW
    • 10.5.2. PRODUCT PORTFOLIO
    • 10.5.3. STRATEGIC INITIATIVES
    • 10.5.4. SCOT ANALYSIS
  • 10.6. TANDEM DIABETES CARE
    • 10.6.1. OVERVIEW
    • 10.6.2. PRODUCT PORTFOLIO
    • 10.6.3. STRATEGIC INITIATIVES
    • 10.6.4. SCOT ANALYSIS
  • 10.7. ECHO THERAPEUTICS INC
    • 10.7.1. OVERVIEW
    • 10.7.2. PRODUCT PORTFOLIO
    • 10.7.3. STRATEGIC INITIATIVES
    • 10.7.4. SCOT ANALYSIS
  • 10.8. ROCHE DIAGNOSTICS
    • 10.8.1. OVERVIEW
    • 10.8.2. PRODUCT PORTFOLIO
    • 10.8.3. STRATEGIC INITIATIVES
    • 10.8.4. SCOT ANALYSIS
  • 10.9. NEMAURA MEDICAL INC
    • 10.9.1. OVERVIEW
    • 10.9.2. PRODUCT PORTFOLIO
    • 10.9.3. STRATEGIC INITIATIVES
    • 10.9.4. SCOT ANALYSIS
  • 10.10. SENSEONICS INC
    • 10.10.1. OVERVIEW
    • 10.10.2. PRODUCT PORTFOLIO
    • 10.10.3. STRATEGIC INITIATIVES
    • 10.10.4. SCOT ANALYSIS
  • 10.11. GLYSENS INC
    • 10.11.1. OVERVIEW
    • 10.11.2. PRODUCT PORTFOLIO
    • 10.11.3. STRATEGIC INITIATIVES
    • 10.11.4. SCOT ANALYSIS
  • 10.12. TERUMO
    • 10.12.1. OVERVIEW
    • 10.12.2. PRODUCT PORTFOLIO
    • 10.12.3. STRATEGIC INITIATIVES
    • 10.12.4. SCOT ANALYSIS
  • 10.13. WOCKHARDT
    • 10.13.1. OVERVIEW
    • 10.13.2. PRODUCT PORTFOLIO
    • 10.13.3. STRATEGIC INITIATIVES
    • 10.13.4. SCOT ANALYSIS
  • 10.14. I-SENS INC
    • 10.14.1. OVERVIEW
    • 10.14.2. PRODUCT PORTFOLIO
    • 10.14.3. STRATEGIC INITIATIVES
    • 10.14.4. SCOT ANALYSIS
  • 10.15. MORPEN LABORATORIES LTD.
    • 10.15.1. OVERVIEW
    • 10.15.2. PRODUCT PORTFOLIO
    • 10.15.3. STRATEGIC INITIATIVE
    • 10.15.4. SCOT ANALYSIS
  • 10.16. APEX BIOTECHNOLOGY CORP.
    • 10.16.1. OVERVIEW
    • 10.16.2. PRODUCT PORTFOLIO
    • 10.16.3. SCOT ANALYSIS
  • 10.17. ARKRAY INC
    • 10.17.1. OVERVIEW
    • 10.17.2. PRODUCT PORTFOLIO
    • 10.17.3. STRATEGIC ANALYSIS
    • 10.17.4. SCOT ANALYSIS
  • 10.18. B BRAUN MELSUNGEN AG
    • 10.18.1. OVERVIEW
    • 10.18.2. PRODUCT PORTFOLIO
    • 10.18.3. SCOT ANALYSIS
    • 10.18.4. STRATEGIC ANALYSIS
  • 10.19. ASCENSIA
    • 10.19.1. OVERVIEW
    • 10.19.2. PRODUCT PORTFOLIO
    • 10.19.3. SCOT ANALYSIS
    • 10.19.4. STRATEGIC ANALYSIS

TABLE LIST

  • TABLE 1 GLOBAL CGMS MARKET BY GEOGRAPHY, 2018-2026($ MILLION)
  • TABLE 2 GLOBAL SMBG MARKET BY GEOGRAPHY, 2018-2026 ($ MILLION)
  • TABLE 3 DIABETES PREVALENCE IN VARIOUS GEOGRAPHIES 2015-2040 (MILLIONS)
  • TABLE 4 GLOBAL CGMS MARKET, BY COMPONENT TYPE, 2018-2026($ MILLION)
  • TABLE 5 GLOBAL CGMS SENSORS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 6 GLOBAL CGMS TRANSMITTERS AND RECEIVERS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 7 GLOBAL CGMS INSULIN PUMP MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 8 GLOBAL CGMS MARKET, BY APPLICATION 2018-2026 ($ MILLION)
  • TABLE 9 GLOBAL CGMS HOME SETTINGS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 10 GLOBAL CGMS DIAGNOSTICS AND CLINICAL MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 11 GLOBAL CGMS HOSPITAL MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 12 IMPORTANT ASPECTS FOR USE OF SMBG DEVICES IN HOME-CARE SETTINGS
  • TABLE 13 SMBG STRIPS USAGE SCENARIO IN SELECTED COUNTRIES IN AMERICAS
  • TABLE 14 PRODUCT MATRIX FOR LANCETS
  • TABLE 15 GLOBAL SMBG MARKET, BY COMPONENT TYPE, 2018-2026 ($ MILLION)
  • TABLE 16 GLOBAL SMBG LANCETS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 17 GLOBAL SMBG HOME SETTING MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 18 GLOBAL SMBG CLINICAL MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 19 GLOBAL SMBG HOSPITALS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 20 GLOBAL SMBG MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 21 GLOBAL CGMS MARKET REVENUE, BY GEOGRAPHY 2018-2026($ MILLION)
  • TABLE 22 CONVERSION RATE USED FOR DIFFERENT CURRENCIES INTO DOLLAR
  • TABLE 23 NORTH AMERICA SMBG MARKET 2018-2026 ($ MILLION)
  • TABLE 24 NORTH AMERICA CGMS MARKET 2018-2026 ($ MILLION)
  • TABLE 25 EUROPE SMBG MARKET 2018-2026 ($ MILLION)
  • TABLE 26 EUROPE CGMS MARKET 2018-2026 ($ MILLION)
  • TABLE 27 GERMANY DIABETIC STATISTICS 2015
  • TABLE 28 AVERAGE PRICES IN GERMANY FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 29 GERMANY SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 30 AVERAGE PRICES IN UK FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 31 UNITED KINGDOM SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 32 ASIA-PACIFIC SMBG MARKET REVENUE 2018-2026($ MILLION)
  • TABLE 33 AVERAGE PRICES IN CHINA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 34 CHINA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 35 AVERAGE PRICES IN INDIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 36 INDIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 37 AVERAGE PRICES IN AUSTRALI FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 38 AUSTRALIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 39 AVERAGE PRICES IN JAPAN FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 40 JAPAN SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 41 AVERAGE PRICES IN SOUTH KOREA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 42 SOUTH KOREA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 43 AVERAGE PRICES IN INDONESIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 44 INDONESIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 45 AVERAGE PRICES IN MALAYSIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 46 MALAYSIA SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 47 AVERAGE PRICES IN PHILIPPINES FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 48 PHILIPPINES SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 49 AVERAGE PRICES IN THAILAND FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 50 THAILAND SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • TABLE 51 AVERAGE PRICES IN VIETNAM FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
  • TABLE 52 VIETNAM SMBG SALES CHANNEL 2018-2026 ($ MILLION)
  • FIGURES LIST
  • FIGURE 1 GLOBAL CGMS SENSORS MARKET, 2018-2026($ MILLION)
  • FIGURE 2 GLOBAL CGMS TRANSMITTERS AND RECEIVERS MARKET, 2018-2026($ MILLION)
  • FIGURE 3 GLOBAL CGMS INSULIN PUMP MARKET, 2018-2026($ MILLION)
  • FIGURE 4 GLOBAL CGMS SHARE, BY APPLICATION 2017 & 2026 (%)
  • FIGURE 5 GLOBAL CGMS HOME SETTING MARKET, 2018-2026($ MILLION)
  • FIGURE 6 GLOBAL CGMS DIAGNOSTICS AND CLINICAL MARKET, 2018-2026($ MILLION)
  • FIGURE 7 GLOBAL CGMS HOSPITAL MARKET, 2018-2026($ MILLION)
  • FIGURE 8 GLOBAL SMBG MARKET SHARE, BY COMPONENT TYPE 2017 & 2026(%)
  • FIGURE 9 GLOBAL SMBG TEST STRIPS MARKET, 2018-2026 ($ MILLION)
  • FIGURE 10 GLOBAL SMBG TEST STRIPS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • FIGURE 11 GLOBAL SMBG GLUCOSE METER MARKET, 2018-2026 ($ MILLION)
  • FIGURE 12 GLOBAL SMBG GLUCOSE METER MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • FIGURE 13 GLOBAL SMBG LANCETS MARKET, 2018-2026 ($ MILLION)
  • FIGURE 14 GLOBAL SMBG MARKET SHARE, BY APPLICATION 2017& 2026(US $ MILLION)
  • FIGURE 15 GLOBAL SMBG HOME SETTING MARKET, 2018-2026 ($ MILLION)
  • FIGURE 16 GLOBAL SMBG CLINICAL MARKET, 2018-2026 ($ MILLION)
  • FIGURE 17 GLOBAL SMBG HOSPITALS MARKET, 2018-2026 ($ MILLION)
  • FIGURE 18 GLOBAL GGMS MARKET SHARE, BY GEOGRAPHY 2017 & 2026 (%)
  • FIGURE 19 NORTH AMERICA CGMS MARKET SHARE, BY COUNTRY 2017 & 2026 (%)
  • FIGURE 20 US CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 21 US SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 22 CANADA CGMS MARKET REVENUE, 2018-2026 ($ MILLION)
  • FIGURE 23 CANADA SMBG MARKET REVENUE, 2018-2026 ($ MILLION)
  • FIGURE 24 EUROPE CGMS MARKET SHARE, BY COUNTRY 2016& 2025 (%)
  • FIGURE 25 GERMANY CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 26 GERMANY SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 27 UK CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 28 UK SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 29 FRANCE CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 30 FRANCE SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 31 REST OF EUROPE (ROE) CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 32 REST OF EUROPE (ROE) SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 33 ASIA-PACIFIC CGMS MARKET REVENUE 2018-2026($ MILLION)
  • FIGURE 34 CHINA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 35 CHINA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 36 INDIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 37 INDIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 38 AUSTRALIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 39 AUSTRALIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 40 DEATHS IN AUSTRALIA DUE TO DIABETES
  • FIGURE 41 JAPAN CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 42 JAPAN SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 43 SOUTH KOREA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 44 SOUTH KOREA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 45 INDONESIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 46 INDONESIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 47 MALAYSIA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 48 MALAYSIA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 49 PHILIPPINES CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 50 PHILIPPINES SMBG MARKET REVENUE, 2018-2026 ($ MILLION)
  • FIGURE 51 THAILAND CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 52 THAILAND SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 53 VIETNAM CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 54 VIETNAM SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 55 REST OF ASIA-PACIFIC CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 56 REST OF ASIA-PACIFIC SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 57 LATIN AMERICA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 58 LATIN AMERICA SMBG MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 59 MEA CGMS MARKET REVENUE, 2018-2026($ MILLION)
  • FIGURE 60 MEA SMBG MARKET REVENUE, 2018-2026($ MILLION)
Back to Top